Sec Form 3 Filing - Versant V Luxco S.a r.l. @ Aprea Therapeutics, Inc. - 2019-10-02

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Versant V Luxco S.a r.l. 2. Issuer Name and Ticker or Trading Symbol Aprea Therapeutics, Inc. [ APRE] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 15 BOULEVARD F.W. RAIFFEISEN, 3. Date of Earliest Transaction (MM/DD/YY) 10/02/2019 (Street) 2411 LUXEMBOURG, N4L-2411 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 12,670 D ( 1 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series B Convertible Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 1,993,658 D ( 1 ) Series C Convertible Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 512,995 D ( 1 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Versant V Luxco S.a r.l. 15 BOULEVARD F.W. RAIFFEISEN 2411 LUXEMBOURG, N4L-2411 X Versant Ventures V, LLC ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Ventures V GP-GP (Canada), Inc. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Ventures V (Canada), L.P. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Ophthalmic Affiliates I, L.P. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Affiliates Fund V, L.P. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Venture Capital V, L.P. ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Versant Venture Capital V (Canada), LP ONE SANSOME STREET SUITE 3630 SAN FRANCISCO, CA94104 X Signatures /s/ Versant V Luxco S.a r.l. By: Robin L. Praeger Its: Manager 10/02/2019 Signature of Reporting Person Date /s/ Versant Ventures V, LLC By: Robin L. Praeger Its: Managing Director 10/02/2019 Signature of Reporting Person Date /s/ Versant Ventures V GP-GP (Canada), Inc. By: Robin L. Praeger Its: Director 10/02/2019 Signature of Reporting Person Date /s/ Versant Ventures V (Canada), L.P. By: Versant Ventures V GP-GP (Canada), Inc. Its: General PartnerBy: Robin L. Praeger Its: Director 10/02/2019 Signature of Reporting Person Date /s/ Versant Venture Capital V (Canada) LP By: Versant Ventures V (Canada), L.P. Its: General PartnerBy: Versant Ventures V GP-GP (Canada), Inc. Its: General Partner By: Robin L. Praeger Its: Director 10/02/2019 Signature of Reporting Person Date /s/ Versant Affiliates Fund V, L.P. By: Versant Ventures V, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director 10/02/2019 Signature of Reporting Person Date /s/ Versant Ophthalmic Affiliates Fund I, L.P. By: Versant Ventures V, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director 10/02/2019 Signature of Reporting Person Date /s/ Versant Venture Capital V, L.P. By: Versant Ventures V, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director 10/02/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein. ( 2 )These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") will automatically be converted into shares of the Issuer's Common Stock, on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock has no expiration date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.